Key points are not available for this paper at this time.
The validated criteria of hematologic response in light-chain (AL) amyloidosis are based on the measurement of circulating free light chains (FLCs). Patients with a difference between involved and uninvolved FLC (dFLC) P P P = .001). Overall survival (OS) was significantly better in the low-dFLC group (median 117 vs 21 months, P P = .005) and with a better RS. A reduction in dFLC after therapy of 20 mg/L baseline. Nineteen percent of newly diagnosed patients with AL amyloidosis have low dFLC and had a better outcome. Hematologic response assessed with adapted criteria predicts OS and RS in these patients, who can thus be assessed for response and included in clinical trials with appropriate stratification.
Milani et al. (Fri,) studied this question.